INT315866

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.21
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 1.02
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endoplasmic reticulum (FLT3)
Anatomy Link Frequency
stem 2
FLT3 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 6 16.00 Low Low
imagery 4 6.76 Low Low
cva 12 5.00 Very Low Very Low Very Low
Pain 12 5.00 Very Low Very Low Very Low
nud 4 5.00 Very Low Very Low Very Low
depression 4 5.00 Very Low Very Low Very Low
Antiemetics 4 5.00 Very Low Very Low Very Low
alcohol 2 5.00 Very Low Very Low Very Low
pain flank 2 5.00 Very Low Very Low Very Low
antidepressant 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hypoxia 6 73.76 Quite High
Cancer 16 68.56 Quite High
Toxicity 22 66.48 Quite High
Renal Cancer 68 63.44 Quite High
Fatigue 26 48.40 Quite Low
Cv Unclassified Under Development 30 47.68 Quite Low
Syndrome 24 45.44 Quite Low
Mucositis 8 42.48 Quite Low
Pressure Volume 2 Under Development 4 41.60 Quite Low
Thrombocytopenia 12 40.16 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
One multitarget agent in this emerging antineoplastic category includes sunitinib, which acts as an intracellular tyrosine kinase inhibitor (TKI) of multiple factors, including the intracellular domain of VEGF receptor (VEGFR-1, VEGFR-2), PDGF receptor (PDGFR-alpha and PDGF-beta), fetal liver tyrosine kinase receptor 3 (FLT3), and KIT (stem-cell factor receptor).9,10
Localization (fetal) of tyrosine kinase receptor 3 in stem
1) Confidence 0.21 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886329 Disease Relevance 0.51 Pain Relevance 0
One multitarget agent in this emerging antineoplastic category includes sunitinib, which acts as an intracellular tyrosine kinase inhibitor (TKI) of multiple factors, including the intracellular domain of VEGF receptor (VEGFR-1, VEGFR-2), PDGF receptor (PDGFR-alpha and PDGF-beta), fetal liver tyrosine kinase receptor 3 (FLT3), and KIT (stem-cell factor receptor).9,10
Localization (fetal) of FLT3 in stem
2) Confidence 0.21 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886329 Disease Relevance 0.51 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox